$1.040
-0.091 (-8.77%)At close
MAIA News
MAIA Events
Selling Stockholders Plan to Sell 751,879 Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 751,879 shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
MAIA Biotechnology Files $150M Mixed Securities Shelf
MAIA Biotechnology files $150M mixed securities shelf
MAIA Biotechnology Announces Initial Efficacy Data from THIO-101 Clinical Trial
MAIA Biotechnology announced initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action drug incorporating telomere targeting and immunogenicity, as a third-line therapy for patients with advanced non-small cell lung cancer. Initial data from the THIO-101 Part C 3L studies1 show a disease control rate of 90.5% in the efficacy evaluable population who had at least one tumor scan after starting treatment. Patients are treated with ateganosine followed by cemiplimab in cycles of 21 days. Current chemotherapy treatments deliver an approximate 25-35% disease control rate. "The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy treatment," said Vlad Vitoc, CEO "Importantly, patients enrolled in Part C of our trial represent a more heavily pre-treated population, with all patients having previously received docetaxel in addition to demonstrating resistance to both immunotherapy and other chemotherapies." MAIA recently announced that it has completed international enrollment in Part C of the Phase 2 THIO-101 expansion trial. Treatment with ateganosine followed by cemiplimab has shown an acceptable safety profile to date in a heavily pre-treated population.
MAIA Biotechnology Activates Third U.S. Clinical Site for THIO-101 Trial
MAIA Biotechnology announced that the third U.S. clinical site in its Phase 2 THIO-101 expansion trial, Winship Cancer Institute of Emory University, is activated and now enrolling patients. The trial studies MAIA's lead investigational telomere-targeting agent, ateganosine, as a third-line treatment for non-small cell lung cancer, NSCLC.
MAIA Biotechnology Receives FDA Approval to Expand THIO-101 Trial
MAIA Biotechnology announced that the U.S. Food and Drug Administration has cleared an amendment to update its investigational new drug application which enables MAIA to open U.S. enrollment for the expansion of the Phase 2 THIO-101 trial of its lead candidate, ateganosine, as a treatment for advanced non-small cell lung cancer. Ateganosine is a novel dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Ateganosine sequenced with a monoclonal antibody checkpoint inhibitor is being evaluated as a therapy for patients in ongoing Phase 2 and Phase 3 clinical trials. MAIA obtained FDA clearance of its updated IND highlighting MAIA's improved efficiencies to its manufacturing capabilities, including new manufacturers, formulation and storage conditions for ateganosine, and MAIA is now cleared to enroll patients in the U.S. for the expansion of the Phase 2 THIO-101 study of patients receiving advanced third-line NSCLC treatment. In addition to the U.S., the THIO-101 study is ongoing at 44 clinical sites in six countries. MAIA recently activated its first U.S. clinical site at Summit Medical Group in New Jersey.
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.